Overview

Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease

Status:
NOT_YET_RECRUITING

Trial end date:
2027-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether a single infusion of tocilizumab is effective in reducing the time to successful weaning from both supplemental oxygen and any respiratory support, in pediatric and adult patients with sickle cell disease (SCD) during acute chest syndrome (ACS).

Phase:

PHASE3

Details

Lead Sponsor:

Assistance Publique - Hpitaux de Paris

Treatments:

Sodium Chloride
tocilizumab